News & Updates
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma
Jupiter, FL, [October 22, 2025] — Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatm...
Read moreMyosin Therapeutics to Engage Clinical Partners at 2025 Society for Neuro-Oncology Annual Meeting
Jupiter, FL — [November 2025] — Myosin Therapeutics, Inc. announced today that Courtney Miller, PhD, Chief Executive Officer and co-founder, and Karen Smith, MD, PhD, Chief Medical Officer, will attend the 2025 Society for Neuro-Oncology (SNO) Annual Meeting this November. While at SNO, Dr. Miller a...
Read moreMyosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Jupiter, FL – [August 19, 2025] – Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) program. The fundi...
Read moreMyosin Therapeutics Publishes Two Foundational Studies in the Journal Cell Highlighting a Novel Approach to Treating Cancer and Brain Disorders
Jupiter, FL – Myosin Therapeutics, a clinical-stage biotechnology company advancing first-in-class therapies targeting molecular motor proteins, announced the publication of two major papers in the journal Cell that establish non-muscle myosin II (NMII) as a druggable target with broad therapeutic i...
Read moreMyosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma
Jupiter, FL – Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for MT-125. The activ...
Read moreMyosin Therapeutics Awarded $3 Million NIH Grant to Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder
Jupiter, FL – Apr 28, 2025, 14:00 ET – Myosin Therapeutics, Inc., a biotechnology company developing innovative therapies for cancer and neurological disorders, today announced that it has been awarded a $3 million grant from the National Institute on Drug Abuse (NIDA), part of the National Institut...
Read moreMyosin Therapeutics Closes Second Seed Round to Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies
JUPITER, Fla., Feb. 26, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3 million to supplement significant investment from the National Institutes of Hea...
Read moreMyosin Therapeutics Announces Key Additions to Its Team as It Prepares to Start Multiple Clinical Trials in Q1 2025
Jupiter, FL - [October 2nd, 2024] – Myosin Therapeutics is pleased to announce the addition of three highly accomplished professionals to its team, further strengthening the company’s expertise as it prepares for upcoming clinical trials. Dr. Alfredo Quinones-Hinojosa has joined as a Scientific Advi...
Read moreMyosin Therapeutics' Patent Portfolio Strengthened with New Issued Statuses in Australia, Japan, Canada, and Korea
Jupiter, FL - [September 12th, 2024] – Myosin Therapeutics is pleased to announce the expansion and strengthening of its patent portfolio for its lead compounds MT-110 and MT-125, with newly granted and issued status in the key jurisdictions of Australia, Japan, Canada, and Korea. These recent grant...
Read moreMyosin Therapeutics Announces Successful Completion of GMP Drug Substance Manufacturing Campaign for MT-125
Jupiter, FL - [August 31st, 2024] – Myosin Therapeutics is pleased to announce that it has successfully completed a Good Manufacturing Practice (GMP) drug substance manufacturing campaign, yielding several kilograms of GMP MT-125 material. This achievement marks a significant step forward in the pre...
Read moreDr. Courtney Miller a Featured Speaker at the BIO International Convention
Jupiter, FL - [May 5th, 2024] – Myosin Therapeutics is proud to announce that Dr. Courtney Miller, CEO and Chair of the Board of Directors, will speak at the BIO International Convention in “Breaking the Cycle: Innovations in Addressing Substance Use Disorder.” The session will bring together leadin...
Read moreToday, Myosin Therapeutics Announces FDA Orphan Drug Designation for MT-125 for the Treatment of Malignant Gliomas
Jupiter, FL - [February 21, 2024] – Today, Myosin Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for MT-125 for the treatment of malignant gliomas, including glioblastoma (GBM), the most common and lethal glioma. Despite...
Read moreMyosin Therapeutics Successfully Transitions to Second Phase of NCI’s Fast Track Funding to Advance MT-125
Jupiter, FL - [January 16, 2024] – After milestone review by the NIH’s National Cancer Institute (NCI), Myosin Therapeutics is excited to announce that it has successfully transitioned to the second phase of funding through the NCI Small Business Technology Transfer (STTR) Fast Track program. Myosin...
Read moreMyosin Therapeutics Transitions MT-110 to GMP Manufacturing After Meeting Milestones in NIH Blueprint Neurotherapeutics Program
Jupiter, FL - [August 1st, 2023] – Myosin Therapeutics is pleased to announce the successful completion of key milestones in the National Institutes of Health (NIH) Blueprint Neurotherapeutics (BPN) Program for its lead compound, MT-110, which is undergoing preclinical testing as a novel therapeutic...
Read moreMyosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder
Jupiter, FL - [March 7th, 2023] – Myosin Therapeutics Inc., a biotechnology company leveraging its innovative platform technology to identify new molecular entities capable of selectively targeting nanomotor proteins, announced today that it supplemented its National Institutes of Health (NIH) fundi...
Read moreMyosin Therapeutics Selected to Present at the 2023 Florida Venture Forum
Jupiter, FL - [January 15th, 2023] – Myosin Therapeutics is honored to announce its selection to present at the prestigious Florida Venture Forum, a premier gathering of the state’s venture capital and private equity professionals. Dr. Pat Griffin, Co-Founder and Member of the Board of Directors at ...
Read moreDr. Courtney Miller Honored with BioFlorida’s 2022 Weaver H. Gaines Entrepreneur of the Year Award
Jupiter, FL - [November 15, 2022] – Myosin Therapeutics is honored to announce that its Chief Executive Officer and Chair of the Board of Directors, Dr. Courtney Miller, received BioFlorida’s 2022 Weaver H. Gaines Entrepreneur of the Year award. This prestigious honor recognizes Dr. Miller’s signifi...
Read more